BBT-176 is under development as a treatmentfor non-small cell lung cancer.
About the drug candidate
BBT-176 is under development as a novel, 4th generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that inhibits the signaling pathway of EGFR with C797S-containing triple mutations.
In April 2021, the company initiated the dose escalation part of its Phase I/II trial, which is being carried out in Korea across three sites. The study and aims to assess the safety, tolerability, and anti-tumor efficacy of the drug candidate in a group of patients with advanced NSCLC. After determining the maximum tolerable dose (MTD) and recommended Phase II dose (RP2D), the dose expansion study will be initiated in both the U.S. and Republic of Korea.
It is estimated that there will be approximately 10,000 to 20,000 new patients per annum with EGFR triple mutations by the mid-2030s and BBT-176 is currently the first-in-class 4th generation EGFR TKI candidate targeting C797S triple mutations.
EventDate of PresentationPresentation
ESMO Congress 2021 - European Society for Medical Oncology
Date of Presentation
2021년 09월 17일
Ask about the clinical studies
What is NSCLC?
Lung cancer is the leading cause of cancer death, accounting for approximately one-fifth of all cancer deaths. There are two main types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), additionally NSCLC accounts for approximately 85% of all lung cancers. Across 8 major countries including the U.S., 5 EU countries, China and Japan, the total NSCLC population as of 2015 is said to be 2 million and the incidence of NSCLC is expected to increase at an annual growth rate of 3.1% from 2015 to 2025. It is known that NSCLC stemming from EGFR mutations and/or overexpressions are more common within the Asian population. In addition, NSCLC can occur due to mutations and/or overexpressions by different proteins such as KRAS, ROS and ALK.